Aminoven Infant 10%

Amino acid solution for parenteral nutrition of pediatric patients

  1. An amino acid solution for parenteral nutrition of preterm & term newborns, babies , infants and young children
  2. Excellent nutritional efficacy for growth and development, with high tolerance and safety.
  3. Contains a well balanced amino acids pattern with:
  • 52% essential amino acids
  • Taurine which is an essential nutrient for neonates
  • Cysteine & tyrosine that are not synthesized in sufficient amounts
  • Low contents of methionine & phenylalanine due to their limited degradation rate

      4.  Further there is no risk of metabolic acidosis and no risk of allergic reactions

  • For partial parenteral nutrition of infants (preterm and term  newborns, babies) and young Children.             
  • May serve as part of total parenteral nutrition together with carbohydrates and fat as energy source, and vitamins, electrolytes and trace elements

Aminoven 10%,100 ml bottle
Age of 1 yr:

1.5 – 2.5 g amino acids/kg body wt = 15 -25 ml/ kg body wt

Age of 2-5 yrs:

1.5 g amino acids/kg body wt =15 ml/kg body wt

Age of 6-14yrs:

1.0 g amino acids/kg body wt =10 ml/kg body wt

Designed to meet special amino acid requirement of pediatric patients which are characterized by

  •  High need for essential amino acids to ensure normal growth
  •  Metabolic immaturity
  •  Taurine is essential for retinal development
  •  Taurine also enhance  bile acid / bile acid flow, thus reducing hepatic insufficiency and cholestasis
  •  Low capacity to compensate for metabolic inadequate amino acid intake

  1. Rino J. Senterre J; Is taurine essential for the neonates ?  Biol Neonate 1977;32:73-6
  2. Kender BS. Taurine: An overview of its role in preventative medicine. Preventative Medicine 1989; 1:79-100
  3. Tyson JE, Lasky R, Flood D, Mize C, Picone T, Paule CL: Randomized trial of taurine supplementation  for infants ≤1,300-gram birth weight: effect on auditory brainstem-evoked responses. Pediatrics 1989;83:406.
  4. Geggel HS. Amend ME, Heckenlively JR. Martin DE, Kopple JD: Nutritional requirement for taurine in patients receiving long-term parenteral nutrition. N. Engl J Med 1985; 312:142-146
  5. Oja, SS Kontro P. Taurine: In Handbook of Neurochemistry. 2nd ed. (A. Lajtha. Ed.)Vol.3.Plenum, New York, 1983. pp501
  6. Sturman JA, Gaull GE: Taurine in the brain and liver of the developing human and monkey. J. Neurochem1975;25:831-835
  7. Sebring L, Huxtable RJ:Taurine modulation of calcium binding to cardiac sarcolemma.J.Pharmacol.Exp.Therap 1985; 232:445-451
  8. Bernardi N: On the role of taurine in the cerebellar cortex: Area-ppraisal, Acta Physiol. Pharmacol. Latinoamer 1985;35:153-164
  9. Cooper A, Betts JM, Periera GR: Taurine deficiency in the severe hepatic dysfunction complicating total parenteral nutrition. J Pediatr Surg 1984;19:462
  10. Meehan JJ, Georgeson KE: Prevention of liver failure in parenteral nutrition-dependent children with short bowel syndrome. J Pediatr Surg 1997;32:473-475
  11. Emudianughe TS, Caldwell J. Smith RL: The utilization of exogenous taurine for the conjugation of xenobiotic acids in the ferret. Xenobiotica 1983;13:133-138
  12. Sturman JA:Taurine in development. J Nutr 1988;118:1169
  13. Gaull GE, Wright CE, Tallan HH: Taurine in human lymphoblastoid cells: uptake and role in proliferation. In Sulfur Amino Acids: Biochemical and Clinical Aspects (Kuriyama RJ. Huxtable and H. Iwata Eds.). A.R. Liss, New York, 1983. pp297
  14. Pasantes-Morales H, Wright CE, Gaull GE: Taurine protection of lymphoblastoid cells from iron-ascorbate-induced damage.  Biochem. Pharmacol 1985;34:2205-2207
  15. Wright GE. Tallan HH, Lin YY: Taurine Biological update. Annu. Rev. Biochem 1985;55:427-453
  16. Thursten JH, Hauhart RE, Dirgo JA: Taurine: A role in osmotic regulation of mammalian brain and possible clinical significance Life Sci 1980;26:1561-1568.
  17. Redmont HP, Stapleton PP, Nearly P, Bouchier-Hayes D: Immuno-nutrition: the role of taurine. Nutrition 1998; 14:599-604
  18. Howard D, Thompson DF: Taurine: an essential amino acid to prevent cholestasis in neonates? Ann Pharmacother 1992; 26:139
  19. Guertin F, Roy CC, Lepage G, Perea A, Giguere R, Yousef I, Tuchweber B: Effect of taurine on total parenteral nutrition-associated cholestasis. JPEN 1991; 15:247-251
  20. Hofmann AF, and Small DM: Detergent properties of bile salts: Correlation with physiological function. Anne Rev. Med 1967; 18:333-376
  21. Stratman C, Goebel HJ, Abel M. Holzki J: Taurine in the new born and infant undergoing surgery. Adv. Exp Med Biol 1995;359:411-2
  22. Teitelbaum DH, Cora AG: Perioperative nutritional support in pediatrics. Nutrition 1998; 14:130-142
  23. Zlotkin SH, Bryan MH, Anderson GH: Cysteine supplemenatation to cysteine free intravenous feeding regimens in newborn infants. AM J Clin Nutr 1981b;43:914
  24. Zoltkin SH, Anderson SH: The development of cystathionase activity during the first year of life. Pediatr Res 1982; 16:65
  25. Clark SE, Karn CA, Ahlrichs JA, Wang J, Leitch CA, Liechty EA, Denne SC: Acute changes is leucine and phenylalanine kinetics produced by parenteral nutrition in premature infants. Pediatr Res 1997;41:568-574
  26. Phase III clinical Trial: Aminoven ®Infant 10%, Fresenius Kabi GmbH, unpublished data 1994
  27. Castillo L, Yu YM, Marchini JS, Chapman TE, Sanchez M, Young VR, Burke JF: Phenylalanine and tyrosine kinetics in critically ill children with sepsis. Pediatr Res 1994;35:580-588
  28. Roberts SA, Ball RO, Filler, RM , Moore AM, Pencharz PB: Phenylalanine and tyrosine metabolism in neonates receiving parenteral nutrition differing in pattern of amino acids, Pediatr Res 1998;44:907-91

Characteristics

Aminoven Infant

AA gms

10g

Taurine

Yes

EAA

52%

NEAA

48%

BCAA

30%

Total Nitrogen (g/l/pack)

1.53

NPE Kcals

Nil

Total Kcals

40K

Osmolarity (mosmol/L)

885

Infusion Rate

2-10 drops/min

Max.Dosage (ml/kg/day)

2.5

Shelf life (months)

24

Route of Adm

central